Trinity Biotech rises on glucose monitoring system data

Trinity Biotech

28/01/2025 15:40

** Shares of biotech firm Trinity Biotech  TRIB.O  rise ~56%
to $1.18
    ** TRIB says its next-generation continuous glucose
monitoring (CGM) system showed superior signal quality, enhanced
reliability and breakthrough accuracy compared to previous
sensors
    ** CGM is for people with Type 1 and Type 2 diabetes aged 18
years and older
    ** Co plans to file for regulatory approval in EU in 2025
and in U.S. in 2026
    ** TRIB fell 60% in 2024

 (Reporting by Kamal Choudhury in Bengaluru)
 ((Kamal.Choudhury@thomsonreuters.com;))